SCHEMBL1506203

SCHEMBL1506203

COC(=O)Cc1cc(Nc2cccc(Cl)c2F)nn1-c1cc(C)nc(C)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 7/20 0.44
▸ NPC1 O15118 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CSF1R P07333 1/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ EGFR P00533 4/20 0.36
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CD38 P28907 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506212 0.91 RIPK1 (0.43) RIPK1CSF1REGFRHDAC3HDAC1
SCHEMBL1506153 0.87 RIPK1 (0.39) RIPK1HDAC3HDAC1HDAC6MAPT
SCHEMBL1506292 0.86 RIPK1 (0.39) RIPK1SMN1; SMN2P2RX3HDAC3HDAC1
SCHEMBL10011414 0.85 KMT2A (0.40) RIPK1EGFRHDAC3HDAC1HDAC6
SCHEMBL1506045 0.84 CYP1A2 (0.40) RIPK1NPC1HPGDEGFRHDAC3
SCHEMBL1506343 0.81 KDM4E (0.37) RIPK1P2RX3EGFR
SCHEMBL10009458 0.80 RIPK1 (0.43) RIPK1TP53SMN1; SMN2P2RX3EGFR
SCHEMBL1506304 0.79 P2RX7 (0.42) RIPK1EGFRHDAC3HDAC1HDAC6
SCHEMBL1506082 0.78 P2RX7 (0.45) RIPK1HDAC3HDAC1HDAC6
SCHEMBL10010359 0.77 P2RX7 (0.40) RIPK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 RIPK1 2211/4885NPC1 2154/4885TP53 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback